{"id":"azd4635","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4594442","moleculeType":"Small molecule","molecularWeight":"315.74"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By inhibiting the adenosine A2A receptor, AZD4635 modulates signaling pathways involved in inflammation and immune responses, which may have therapeutic benefits in certain diseases.","oneSentence":"AZD4635 is a small molecule inhibitor of the adenosine A2A receptor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:30:18.565Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT03381274","phase":"PHASE1, PHASE2","title":"Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedImmune LLC","startDate":"2018-05-08","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":43},{"nctId":"NCT04089553","phase":"PHASE2","title":"An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-08-29","conditions":"Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":59},{"nctId":"NCT04495179","phase":"PHASE2","title":"A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-08-04","conditions":"Progressive Metastatic Castrate-Resistant Prostate Cancer","enrollment":30},{"nctId":"NCT02740985","phase":"PHASE1","title":"A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-17","conditions":"Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)","enrollment":313},{"nctId":"NCT04478513","phase":"PHASE1","title":"A Study to Assess the Effect of Fluvoxamine and Smoking on Pharmacokinetics ( the Movement of Drugs Within the Body) of AZD4635 in Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-07-21","conditions":"Healthy Volunteer/DDI Study","enrollment":28},{"nctId":"NCT03980821","phase":"PHASE1","title":"A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-07-04","conditions":"Advanced Solid Malignancies","enrollment":10},{"nctId":"NCT03710434","phase":"PHASE1","title":"AZD4635 Relative Bioavailability Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-11-01","conditions":"Healthy Volunteers","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AZD4635","genericName":"AZD4635","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD4635 is a small molecule inhibitor of the adenosine A2A receptor. Used for Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":6,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}